Aurinia Pharmaceuticals
AUPH
179 hedge funds and large institutions have $281M invested in Aurinia Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 47 increasing their positions, 63 reducing their positions, and 38 closing their positions.
0% less ownership
Funds ownership: 38.61% → 38.61% (-0%)
6% less funds holding
Funds holding: 191 → 179 (-12)
25% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 63
29% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 38
35% less call options, than puts
Call options by funds: $8.72M | Put options by funds: $13.4M
44% less capital invested
Capital invested by funds: $498M → $281M (-$217M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18.5M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5M |
| 4 |
6CM
683 Capital Management
New York
|
+$2.68M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.71M |
| 3 |
Citigroup
New York
|
-$4.46M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.06M |
| 5 |
Jane Street
New York
|
-$3.21M |
AUPH Hedge Fund Activity: Q1 2024 in Review
179 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2024, worth a combined $281M — down 44% from $498M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of AUPH and 27 opened new positions — a net loss of 11 holders — while 63 trimmed existing stakes and 47 added.
The largest buyer was Armistice Capital, adding an estimated $18.5M. The largest seller was Morgan Stanley, cutting an estimated $10.9M.
- 179 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2024, down from 191 in Q4 2023.
- Funds reported $281M of Aurinia Pharmaceuticals stock for Q1 2024, down 44% quarter-over-quarter.
- 27 funds opened new Aurinia Pharmaceuticals positions in Q1 2024 and 38 closed out, a net change of -11 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2024 was Armistice Capital, an estimated $18.5M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2024.